Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 15-22

  Pamuk, Omer Nuri ^a   Can, Guray ^a   Ayvaz, Suleyman ^a   Karaca, Turan ^a   Pamuk, Gulsum Emel ^a   Demirtas, Selim ^a   Tsokos, George C ^b  

^a TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bleomycin; Fibrosis; Fostamatinib; Scleroderma

Indexed keywords

BLEOMYCIN; FOSTAMATINIB; PROTEIN KINASE SYK; TRANSFORMING GROWTH FACTOR BETA; FC RECEPTOR; IMMUNOGLOBULIN E; OXAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; SIGNAL PEPTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME PHOSPHORYLATION; FIBROSIS; HISTOPATHOLOGY; INFLAMMATION; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SKIN FIBROSIS; SKINFOLD THICKNESS; TISSUE INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROTECTION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; LUNG; MAST CELL; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN;

ANIMALS; BLEOMYCIN; CYTOPROTECTION; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN E; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MAST CELLS; MICE, INBRED C57BL; OXAZINES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PULMONARY FIBROSIS; PYRIDINES; RECEPTORS, FC; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84946218351     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. MOINZADEH P, ABERER E, AHMADI-SIMAB K et al.: Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2015; 74: 730-7.
2. MATUCCI-CERINIC M, KAHALEH B, WIGLEY FM: Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013; 65: 1953-62.
3. VARGA J, ABRAHAM D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
4. HESSELSTRAND R, SCHEJA A, AKESSON A: Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-6.
5. ROSENBLOOM J, CASTRO SV, JIMENEZ SA: Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010; 152: 159-66.
6. VARGA J, PASCHE B: Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-6.
7. BARONI SS, SANTILLO M, BEVILACQUA F et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-76.
8. MAN XY, FINNSON KW, BARON M, PHILIP A: CD109, a TGF-B co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther 2012; 14: R144.
9. VORSTENBOSCH J, Al-AJMI H, WINOCOUR S, TRZECIAK A, LESSARD L, PHILIP A: CD109 overexpression ameliorates skin fibrosis in a Mouse model of bleomycin-induced scleroderma. Arthritis Rheum 2013; 65: 1378-83.
10. DENTON CP, MERKEL PA, FURST DE et al.: Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-33.
11. DISTLER JHW, DISTLER O: Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology 2008; 47 (Suppl. 5): v10-1.
12. AKHMETSHINA A, VENALIS P, DEES C et al.: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
13. DISTLER JH, JUNGEL A, HUBER LC et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22.
14. SPIERA RF, GORDON JK, MERSTEN JN et al.: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70: 1003-9.
15. KAY J, HIGH WA: Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58: 2543-8.
16. MAGRO L, MOHTY M, CATTEAU B et al.: Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114: 719-22.
17. GORDON J, UDEH U, DOOBAY K et al.: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S189-93.
18. PAMUK ON, TSOKOS GC: Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res Ther 2010; 12: 222.
19. MóCSAI A, RULAND J, TYBULEWICZ VL: The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010; 10: 387-402.
20. BERTON G, MOSCAI A, LOWELL CA: Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol 2005; 26: 209-13.
21. KYTTARIS VC, TSOKOS GC: Syk kinase as a treatment target for therapy in autoimmune diseases. Clin Immunol 2007; 124: 235-7.
22. TOHYAMA Y, YAMAMURA H: Complement-mediated phagocytosis -the role of Syk. IUBMB Life 2006; 58: 304-8.
23. BRASELMANN S, TAYLOR V, ZHAO H et al.: R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006; 319: 998-1008.
24. BAHJAT FR, PINE PR, REITSMA A et al.: An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008; 58: 1433-44.
25. DENG GM, LIU L, BAHJAT R, PINE PR, TSOKOS GC: Inhibition of spleen tyrosine kinase suppresses skin and kidney disease in lupus prone mice. Arthritis Rheum 2010; 62: 2086-92.
26. WEINBLATT ME, KAVANAUGH A, BURGOS-VARGAS R et al.: Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 3309-18.
27. WEINBLATT ME, KAVANAUGH A, GENOVESE MC, MUSSER TK, GROSSBARD EB, MAGILAVY DB: An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363: 1303-12.
28. SFIKAKIS PP, McCUNE BK, TSOKOS M, ARONI K, VAYIOPOULOS G, TSOKOS GC: Immuno-histological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993; 69: 199-204.
29. HUGLE T, HOGAN V, WHITE KE, van LAAR JM: Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2011; 63: 795-9.
30. SKIRTLADZE C, DISTLER O, DEES C et al.: Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58: 1475-84.
31. PILLING D, TUCKER NM, GOMER RH: Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 2006; 79: 1242-51.
32. LE HD, KIMURA H, DATE M et al.: Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. J Dermatol Sci 2014; 74: 214-21.
33. CHA HS, BOYLE DL, INOUE T et al.: A novel spleen tyrosine inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006; 317: 571-8.
34. MATSUBARA S, LI G, TAKEDA K et al.: Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006; 173: 56-63.
35. MATSUBARA S, KOYA T, TAKEDA K et al.: Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2006; 34: 426-33.
36. IHN H: Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008; 49: 103-13.
37. LEASK A, ABRAHAM DJ: TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
38. PARK GB, KIM D, KIM YS et al.: The Epstein-Barr virus causes epithelial-mesenchymal transition in human corneal epithelial cells via Syk/src and Akt/Erk signaling pathways. Invest Ophthalmol Vis Sci 2014; 55: 1770-9.
39. YANG WS, CHANG JW, HAN NJ, LEE SK, PARK SK: Spleen tyrosine kinase mediates high glucose-induced transforming growth factor-β1 up-regulation in proximal tubular epithelial cells. Exp Cell Res 2012; 318: 1867-76.